53726-14-0

Basic information

• Product Name: 2-Aminobutanamide
• Synonyms: 2-Amino-n-butanamide;2-Aminobutanamide;DL-2-Aminobutyramide;ButanaMide, 2-aMino-
• CAS NO: 53726-14-0
• Molecular Formula: C₄H₁₀N₂O
• Molecular Weight: 102.14
• Mol File: 53726-14-0.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 246 ºC
• Flash Point: 102 ºC
• Appearance: white solid
• Density: 1.027
• Vapor Pressure: 0.0282mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: 2-8°C(protect from light)
• PKA: 16.07±0.50(Predicted)
• CAS DataBase Reference: 2-Aminobutanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Aminobutanamide(53726-14-0)
• EPA Substance Registry System: 2-Aminobutanamide(53726-14-0)

Safety Data

• Hazardous Substances Data: 53726-14-0(Hazardous Substances Data)

Usage

General Description

2-Aminobutanamide, also known as 2-AB, is a chemical compound with the molecular formula C4H10N2O. It is a derivative of the amino acid alanine and is classified as an amide. 2-AB is commonly used in the field of biotechnology as a labeling reagent for glycoproteins, specifically for the analysis and identification of glycans. It has also been utilized in research related to cancer, cardiovascular diseases, and diabetes. 2-Aminobutanamide is a versatile chemical with various applications in biochemistry and medicine due to its ability to specifically label glycoproteins.

InChI:InChI=1/C4H10N2O/c1-2-3(5)4(6)7/h3H,2,5H2,1H3,(H2,6,7)

Upstream product

• 53726-14-0 (S)-2-amino-butanamide hydrochloride 
• 7324-11-0 (S)-2-amino-butanamide 
• 87-69-4 L-Tartaric acid 
• 2483-62-7 (S)-2-aminobutyric acid methyl ester 
• 868134-59-2 L-2-aminobutanamide tartaric acid 
• 945472-53-7 (S)-2-aminobutyramide D-mandelic acid salt 
• 7682-18-0 (S)-2-aminobutyric acid methyl ester hydrochloride 
• 4510-08-1 L-methioninamide 
• 40651-89-6 2-aminobutyronitrile 
• 2835-81-6 2-aminobutanoic acid 
• 5959-29-5 S-(+)-2-amino-n-butyric acid hydrochloride 
• 7623-11-2 2-chlorobutyryl chloride 
• 7462-73-9 2-chlorobutyramide 
• 22621-37-0 ethyl 2-aminobutyrate 

Downstream Products

• 102767-28-2 levetiracetam 
• 357336-20-0 brivaracetam 
• 357336-99-3 ((2S)-2-[(4S)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide) 
• 7324-11-0 (S)-2-amino-butanamide 
• 53726-14-0 (S)-2-amino-butanamide hydrochloride 
• 113902-41-3 2-hydroxy-3-ethyl-5,6,7,8-tetrahydro quinoxaline 
• 123952-17-0 Boc-Tyr-Abu-NH₂ 
• 4426-48-6 1,2-butanediamine 
• 93554-80-4 2-aminobutyronitrile hydrochloride 
• 1235408-31-7 (2S)-2-[(4-bromo-2-nitro-phenyl)amino]butanamide 
• 1076190-33-4 methyl 4-{[(1S)-1-(aminocarbonyl)propyl]amino}-3-phenylbutanoate 

Relevant articles and documents

Method for synthesizing medicine for treating epilepsy by using L-2-aminobutanamide hydrochloride

The invention discloses a method for synthesizing a medicine for treating epilepsy by using L-2-aminobutanamide hydrochloride, and relates to the technical field of medicine synthesis, and the method comprises the following steps: under the protection of nitrogen, adding L-2-aminobutanamide hydrochloride and 4-chlorobutyrate into isopropyl alcohol, and reacting under the action of an alkaline substance and a catalyst, heating and refluxing to carry out nucleophilic substitution reaction and ring-closure reaction to prepare the levetiracetam. According to the method, the levetiracetam is synthesized by adopting a milder alkaline substance and a one-pot method, the operation is simple, the levetiracetam can be prepared without post-treatment, the levetiracetam obtained by the method is low in impurity content and high in chemical purity, the yield can reach 83.43% or above, and the purity reaches 99.6%.

Method for splitting aminobutanamide by using ammonium hydrogen tartrate

The present invention relates to the technical field of aminobutanamide resolution, and discloses a method for resolving aminobutanamide by using ammonium hydrogen tartrate, and the method comprises the following steps: taking 10-20 parts of ammonium tartrate, placing ammonium tartrate in a reaction flask, adding 20-40 parts of purified water, and performing stirring for 0.5-1.5 h to obtain an ammonium tartrate solution. According to the method for resolving aminobutanamide by using ammonium hydrogen tartrate, the ammonium hydrogen tartrate is used as a reactant and is subjected to resolution reaction with racemic 2-aminobutanamide, and an L-2-aminobutanamide ammonium hydrogen tartrate wet product obtained after the reaction is reacted with methanol and ammonia gas, so L-2-aminobutanamide and ammonium hydrogen tartrate can be separated out; the L-2-aminobutanamide liquid can be obtained, the ammonium hydrogen tartrate can be converted into the ammonium tartrate solid for recovery and storage, and the L-2-aminobutanamide solid can be used for splitting the aminobutanamide in the next ammonium hydrogen tartrate preparation so as to achieve the recovery and reutilization of the reactants, such that the production cost is reduced, and the low cost purpose is achieved.

Method for preparing levetiracetam

The invention relates to a method for preparing levetiracetam. The method comprises the following steps: reacting aminobutyric acid in lower alcohol and thionyl chloride to obtain an intermediate I; adding ammonia water to continue the reaction, and adding hydrochloric acid to adjust the pH value to about 3 to salify to obtain a salified intermediate II refined product; reacting the intermediate II in the presence of KOH in the presence of a catalyst and dichloromethane, and then adding 4-chlorobutyryl chloride to continuously react; adding water to hydrolyze, adjusting the pH to be weakly alkaline by using diluted hydrochloric acid, and crystallizing to obtain a levetiracetam crude product; decolorizing and crystallizing in ethyl acetate to obtain a refined product of levetiracetam. The invention also relates to the levetiracetam prepared by the method and pharmaceutical application thereof, for example, the levetiracetam can be used for treating or preventing epilepsy, Parkinson's disease, dyskinesia, migraine, tremor, idiopathic tremor, bipolar disorder, chronic pain, neuropathic pain, or bronchial, asthma or allergic diseases.